Abstract:Viran Jayanetti, 1 Sartaj Sandhu, 2 Jed A Lusthaus 3 1 Prince of Wales Hospital, Sydney, New South Wales, Australia; 2 Sydney Eye Hospital, Sydney, New South Wales, Australia; 3 Glaucoma Unit, Sydney Eye Hospital, Sydney, New South Wales, Australia Correspondence: Jed A Lusthaus Glaucoma Unit, Sydney Eye Hospital, Sydney, New South Wales, Australia Email jed.lusthaus@sydney.edu.au Glaucoma causes irreversible vision loss, with elevated intraocular pressure (IOP) being the only known modifiable risk factor. There are a variety of medical and interventional options for lowering IOP; however, despite these treatments, glaucoma continues to be a leading cause of visual impairment. Further research continues to strive for treatment options with improved side effect profiles, additional IOP-lowering effects, and ease of use. This review provides a brief summary of current IOP-lowering therapies and then outlines pipeline ocular hypotensive agents, their mechanisms of action, benefits, and side effect profiles. Advancements are seen within currently used eye drop classes such as prostaglandin analogues, Rho kinase inhibitors and nitric oxide donors, whilst there are also new drug classes, such as tyrosine protein kinase activators. Most developing drugs are topical drop formulations, with a number already having entered Phase III trials. Alternative drug delivery methods are also in development and will be briefly discussed. Pharmacological and drug delivery developments continue to provide glaucoma patients and clinicians with new options and the promise of better outcomes, particularly in terms of improved tolerance and reduced frequency of dosing. Keywords: glaucoma, ocular hypertension, intraocular pressure, ocular hypotensive drugs

Chemical Insights into Topical Agents in Intraocular Pressure Management: From Glaucoma Etiopathology to Therapeutic Approaches

Topical Medication Therapy for Glaucoma and Ocular Hypertension

The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma

Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment

Current opinion in ophthalmology: novel glaucoma devices in the pipeline

Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review

Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma

Newer advances in medical management of glaucoma

Alternatives to Topical Glaucoma Medication for Glaucoma Management

New classes of glaucoma medications

Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action

Glaucoma: A review of current management, patients’ adherence, direct and indirect cost, and barriers to drug delivery

Consideration of Several Problems in Clinical Application of Prostaglandin Analogues in Lowering Intraocular Pressure

Current management of glaucoma

An Emerging Multi-mechanism and Multi-modal Approach in Interventional Glaucoma Therapy

Impact of combination of local carbonic anhydrase inhibitors and beta-blockers on intraocular pressure, visual functions and eye hemodynamics in primary open-angle glaucoma

Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research

Sustained release ocular drug delivery systems for glaucoma therapy

Glaucoma: Current treatment and impact of advanced drug delivery systems

In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy

The advances of the expert consensus and the first-line medications of topical intraocular pressure-lowering agents in glaucoma treatment